BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 9067756)

  • 1. Three germline mutations in the TP53 gene.
    Cornelis RS; van Vliet M; van de Vijver MJ; Vasen HF; Voute PA; Top B; Khan PM; Devilee P; Cornelisse CJ
    Hum Mutat; 1997; 9(2):157-63. PubMed ID: 9067756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.
    Birch JM; Blair V; Kelsey AM; Evans DG; Harris M; Tricker KJ; Varley JM
    Oncogene; 1998 Sep; 17(9):1061-8. PubMed ID: 9764816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
    Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
    Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.
    Varley JM; McGown G; Thorncroft M; Santibanez-Koref MF; Kelsey AM; Tricker KJ; Evans DG; Birch JM
    Cancer Res; 1997 Aug; 57(15):3245-52. PubMed ID: 9242456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
    Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
    Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
    Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
    Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
    Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
    Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome.
    Barlow JW; Mous M; Wiley JC; Varley JM; Lozano G; Strong LC; Malkin D
    Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1403-6. PubMed ID: 15298965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel p53 germline alteration identified in a late onset breast cancer kindred.
    Sun XF; Johannsson O; Håkansson S; Sellberg G; Nordenskjöld B; Olsson H; Borg A
    Oncogene; 1996 Jul; 13(2):407-11. PubMed ID: 8710380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation.
    Salmon A; Amikam D; Sodha N; Davidson S; Basel-Vanagaite L; Eeles RA; Abeliovich D; Peretz T
    Clin Oncol (R Coll Radiol); 2007 Sep; 19(7):490-3. PubMed ID: 17572079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
    Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
    Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Li-Fraumeni syndrome: an inherited susceptibility to cancer.
    Evans SC; Lozano G
    Mol Med Today; 1997 Sep; 3(9):390-5. PubMed ID: 9302689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 mutation and haplotype analysis of two large African American families.
    Hung J; Mims B; Lozano G; Strong L; Harvey C; Chen TT; Stastny V; Tomlinson G
    Hum Mutat; 1999; 14(3):216-21. PubMed ID: 10477429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel TP53 mutations in familial and sporadic cancer cases of German and Swiss origin.
    Bendig I; Mohr N; Kramer F; Weber BH
    Cancer Genet Cytogenet; 2004 Oct; 154(1):22-6. PubMed ID: 15381368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and functional studies of a germline TP53 splicing mutation in a Li-Fraumeni-like family.
    Varley JM; Chapman P; McGown G; Thorncroft M; White GR; Greaves MJ; Scott D; Spreadborough A; Tricker KJ; Birch JM; Evans DG; Reddel R; Camplejohn RS; Burn J; Boyle JM
    Oncogene; 1998 Jun; 16(25):3291-8. PubMed ID: 9681828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of de novo mutations in Li-Fraumeni syndrome.
    Gonzalez KD; Buzin CH; Noltner KA; Gu D; Li W; Malkin D; Sommer SS
    J Med Genet; 2009 Oct; 46(10):689-93. PubMed ID: 19556618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balanced t(11;15)(q23;q15) in a TP53+/+ breast cancer patient from a Li-Fraumeni syndrome family.
    Sherif ZA; Danielsen M
    Cancer Genet Cytogenet; 2006 Jul; 168(1):50-8. PubMed ID: 16772121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites.
    Rapakko K; Allinen M; Syrjäkoski K; Vahteristo P; Huusko P; Vähäkangas K; Eerola H; Kainu T; Kallioniemi OP; Nevanlinna H; Winqvist R
    Br J Cancer; 2001 Jan; 84(1):116-9. PubMed ID: 11139324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.